Financhill
Sell
21

HEPA Quote, Financials, Valuation and Earnings

Last price:
$0.07
Seasonality move :
-9.8%
Day range:
$0.07 - $0.08
52-week range:
$0.07 - $68.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.35x
Volume:
62.5K
Avg. volume:
3.1M
1-year change:
-99.87%
Market cap:
$779.3K
Revenue:
--
EPS (TTM):
-$80.50

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
HEPA
Hepion Pharmaceuticals
-- -- -- -- --
CRMD
Cormedix
$36M $0.25 3606.46% -38.24% $16.83
FBIO
Fortress Biotech
$11.6M -$0.44 -2.43% -57.53% $10.00
KRYS
Krystal Biotech
$96.2M $1.52 38.78% 138.36% $205.20
PTIX
Protagenic Therapeutics
-- -- -- -- --
RIGL
Rigel Pharmaceuticals
$43.9M $0.09 86.28% 1057.82% $33.74
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
HEPA
Hepion Pharmaceuticals
$0.07 -- $779.3K -- $0.00 0% --
CRMD
Cormedix
$12.53 $16.83 $849.8M 56.95x $0.00 0% 9.37x
FBIO
Fortress Biotech
$1.83 $10.00 $54.1M -- $0.00 0% 0.72x
KRYS
Krystal Biotech
$126.45 $205.20 $3.7B 30.40x $0.00 0% 11.32x
PTIX
Protagenic Therapeutics
$3.94 -- $2.3M -- $0.00 0% 0.13x
RIGL
Rigel Pharmaceuticals
$19.62 $33.74 $350.7M 9.48x $0.00 0% 1.72x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
HEPA
Hepion Pharmaceuticals
-- 5.387 -- --
CRMD
Cormedix
-- 2.314 -- 3.84x
FBIO
Fortress Biotech
72.36% 0.006 103.39% 1.49x
KRYS
Krystal Biotech
-- 1.447 -- 9.06x
PTIX
Protagenic Therapeutics
-- 0.770 -- --
RIGL
Rigel Pharmaceuticals
76.29% 6.907 18.59% 1.78x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
HEPA
Hepion Pharmaceuticals
-- -$1.3M -- -- -- -$1.1M
CRMD
Cormedix
$37.5M $20.1M 23.7% 23.7% 52.85% $19.7M
FBIO
Fortress Biotech
$8.3M -$22.3M -67.58% -- -168.82% -$19.6M
KRYS
Krystal Biotech
$83.2M $36.2M 13.91% 13.91% 41.03% $24.8M
PTIX
Protagenic Therapeutics
-- -$1.4M -- -- -- -$1.1M
RIGL
Rigel Pharmaceuticals
$48.9M $12.8M 76.12% -- 25.06% -$893K

Hepion Pharmaceuticals vs. Competitors

  • Which has Higher Returns HEPA or CRMD?

    Cormedix has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 52.82%. Hepion Pharmaceuticals's return on equity of -- beat Cormedix's return on equity of 23.7%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    CRMD
    Cormedix
    95.91% $0.30 $114.9M
  • What do Analysts Say About HEPA or CRMD?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Cormedix has an analysts' consensus of $16.83 which suggests that it could grow by 34.34%. Given that Hepion Pharmaceuticals has higher upside potential than Cormedix, analysts believe Hepion Pharmaceuticals is more attractive than Cormedix.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    CRMD
    Cormedix
    3 0 0
  • Is HEPA or CRMD More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Cormedix has a beta of 1.538, suggesting its more volatile than the S&P 500 by 53.821%.

  • Which is a Better Dividend Stock HEPA or CRMD?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cormedix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Cormedix pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or CRMD?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Cormedix quarterly revenues of $39.1M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Cormedix's net income of $20.6M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Cormedix's PE ratio is 56.95x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 9.37x for Cormedix. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    CRMD
    Cormedix
    9.37x 56.95x $39.1M $20.6M
  • Which has Higher Returns HEPA or FBIO?

    Fortress Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of -80.55%. Hepion Pharmaceuticals's return on equity of -- beat Fortress Biotech's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    FBIO
    Fortress Biotech
    63.54% -$0.48 $90.7M
  • What do Analysts Say About HEPA or FBIO?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Fortress Biotech has an analysts' consensus of $10.00 which suggests that it could grow by 446.45%. Given that Hepion Pharmaceuticals has higher upside potential than Fortress Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Fortress Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    FBIO
    Fortress Biotech
    1 0 0
  • Is HEPA or FBIO More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Fortress Biotech has a beta of 1.853, suggesting its more volatile than the S&P 500 by 85.291%.

  • Which is a Better Dividend Stock HEPA or FBIO?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fortress Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Fortress Biotech pays out -10.24% of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or FBIO?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Fortress Biotech quarterly revenues of $13.1M. Hepion Pharmaceuticals's net income of -$6.1M is higher than Fortress Biotech's net income of -$10.6M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Fortress Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.72x for Fortress Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    FBIO
    Fortress Biotech
    0.72x -- $13.1M -$10.6M
  • Which has Higher Returns HEPA or KRYS?

    Krystal Biotech has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 40.52%. Hepion Pharmaceuticals's return on equity of -- beat Krystal Biotech's return on equity of 13.91%.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    KRYS
    Krystal Biotech
    94.3% $1.20 $984.7M
  • What do Analysts Say About HEPA or KRYS?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Krystal Biotech has an analysts' consensus of $205.20 which suggests that it could grow by 62.28%. Given that Hepion Pharmaceuticals has higher upside potential than Krystal Biotech, analysts believe Hepion Pharmaceuticals is more attractive than Krystal Biotech.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    KRYS
    Krystal Biotech
    8 1 0
  • Is HEPA or KRYS More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Krystal Biotech has a beta of 0.787, suggesting its less volatile than the S&P 500 by 21.292%.

  • Which is a Better Dividend Stock HEPA or KRYS?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Krystal Biotech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or KRYS?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Krystal Biotech quarterly revenues of $88.2M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Krystal Biotech's net income of $35.7M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Krystal Biotech's PE ratio is 30.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 11.32x for Krystal Biotech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    KRYS
    Krystal Biotech
    11.32x 30.40x $88.2M $35.7M
  • Which has Higher Returns HEPA or PTIX?

    Protagenic Therapeutics has a net margin of -- compared to Hepion Pharmaceuticals's net margin of --. Hepion Pharmaceuticals's return on equity of -- beat Protagenic Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    PTIX
    Protagenic Therapeutics
    -- -$2.75 --
  • What do Analysts Say About HEPA or PTIX?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Protagenic Therapeutics has an analysts' consensus of -- which suggests that it could grow by 5585.28%. Given that Hepion Pharmaceuticals has higher upside potential than Protagenic Therapeutics, analysts believe Hepion Pharmaceuticals is more attractive than Protagenic Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    PTIX
    Protagenic Therapeutics
    0 0 0
  • Is HEPA or PTIX More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Protagenic Therapeutics has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.318%.

  • Which is a Better Dividend Stock HEPA or PTIX?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protagenic Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Protagenic Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or PTIX?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Protagenic Therapeutics quarterly revenues of --. Hepion Pharmaceuticals's net income of -$6.1M is lower than Protagenic Therapeutics's net income of -$1.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Protagenic Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 0.13x for Protagenic Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    PTIX
    Protagenic Therapeutics
    0.13x -- -- -$1.4M
  • Which has Higher Returns HEPA or RIGL?

    Rigel Pharmaceuticals has a net margin of -- compared to Hepion Pharmaceuticals's net margin of 21.46%. Hepion Pharmaceuticals's return on equity of -- beat Rigel Pharmaceuticals's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    HEPA
    Hepion Pharmaceuticals
    -- -$2.15 --
    RIGL
    Rigel Pharmaceuticals
    91.73% $0.63 $78.3M
  • What do Analysts Say About HEPA or RIGL?

    Hepion Pharmaceuticals has a consensus price target of --, signalling upside risk potential of 2112576.06%. On the other hand Rigel Pharmaceuticals has an analysts' consensus of $33.74 which suggests that it could grow by 71.98%. Given that Hepion Pharmaceuticals has higher upside potential than Rigel Pharmaceuticals, analysts believe Hepion Pharmaceuticals is more attractive than Rigel Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    HEPA
    Hepion Pharmaceuticals
    0 0 0
    RIGL
    Rigel Pharmaceuticals
    1 4 0
  • Is HEPA or RIGL More Risky?

    Hepion Pharmaceuticals has a beta of 1.897, which suggesting that the stock is 89.73% more volatile than S&P 500. In comparison Rigel Pharmaceuticals has a beta of 1.337, suggesting its more volatile than the S&P 500 by 33.678%.

  • Which is a Better Dividend Stock HEPA or RIGL?

    Hepion Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rigel Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hepion Pharmaceuticals pays -- of its earnings as a dividend. Rigel Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios HEPA or RIGL?

    Hepion Pharmaceuticals quarterly revenues are --, which are smaller than Rigel Pharmaceuticals quarterly revenues of $53.3M. Hepion Pharmaceuticals's net income of -$6.1M is lower than Rigel Pharmaceuticals's net income of $11.4M. Notably, Hepion Pharmaceuticals's price-to-earnings ratio is -- while Rigel Pharmaceuticals's PE ratio is 9.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hepion Pharmaceuticals is -- versus 1.72x for Rigel Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    HEPA
    Hepion Pharmaceuticals
    -- -- -- -$6.1M
    RIGL
    Rigel Pharmaceuticals
    1.72x 9.48x $53.3M $11.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Palo Alto Networks Stock Be in 5 Years?
Where Will Palo Alto Networks Stock Be in 5 Years?

You know those companies that just refuse to slow down…

UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?
UPS Stock Forecast: Is the 6.9% Dividend Too Good to Be True?

Parcel delivery giant UPS (NYSE:UPS) has seen its fair share…

Where Will Coinbase Stock Be in 5 Years?
Where Will Coinbase Stock Be in 5 Years?

If you’ve been anywhere near the crypto world over the…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
84
SBET alert for May 28

SharpLink Gaming [SBET] is up 454.46% over the past day.

Buy
63
X alert for May 28

United States Steel [X] is up 2.02% over the past day.

Sell
37
ATS alert for May 28

ATS [ATS] is up 19.57% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock